Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly

Paying $675m Upfront For Rights To RET Inhibitor

 
• By Kevin Grogan
  
Gears_Sunlight
Roche looks a good fit for marketing pralsetinib • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business